Počet záznamů: 1  

Trisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1

  1. 1.
    SYSNO ASEP0482957
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevTrisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1
    Tvůrce(i) Malínková, Veronika (UEB-Q) ORCID, RID
    Řezníčková, Eva (UEB-Q) RID, ORCID
    Jorda, Radek (UEB-Q) ORCID, RID
    Gucký, T. (CZ)
    Kryštof, Vladimír (UEB-Q) RID, ORCID
    Celkový počet autorů5
    Zdroj.dok.Bioorganic & Medicinal Chemistry. - : Elsevier - ISSN 0968-0896
    Roč. 25, č. 24 (2017), s. 6523-6535
    Poč.str.13 s.
    Jazyk dok.eng - angličtina
    Země vyd.GB - Velká Británie
    Klíč. slovadependent kinase inhibitors ; src tyrosine kinase ; 2,6,9-trisubstituted purines ; therapeutic target ; potent inhibitor ; imatinib ; leukemia ; mutations ; mutant ; domain
    Vědní obor RIVEB - Genetika a molekulární biologie
    Obor OECDHematology
    CEPLO1204 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy
    Institucionální podporaUEB-Q - RVO:61389030
    UT WOS000415984900027
    DOI10.1016/j.bmc.2017.10.032
    AnotaceInhibition of protein kinases is a validated concept for pharmacological intervention in cancers. Many kinase inhibitors have been approved for clinical use, but their practical application is often limited. Here, we describe a collection of 23 novel 2,6,9-trisubstituted purine derivatives with nanomolar inhibitory activities against PDGFR alpha, a receptor tyrosine kinase often found constitutively activated in various tumours. The compounds demonstrated strong and selective cytotoxicity in the human eosinophilic leukemia cell line EOL-1, whereas several other cell lines were substantially less sensitive. The cytotoxicity in EOL-1, which is known to express the FIP1L1-PDGFR alpha fusion gene encoding an oncogenic kinase, correlated significantly with PDGFR alpha inhibition. EOL-1 cells treated with the compounds also exhibited dose-dependent inhibition of PDGFR alpha autophosphorylation and suppression of its downstream signaling pathways with concomitant G1 phase arrest, confirming the proposed mechanism of action. Our results show that substituted purines can be used as platforms for preparing tyrosine kinase inhibitors with specific activity towards eosinophilic leukemia.
    PracovištěÚstav experimentální botaniky
    KontaktDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Rok sběru2018
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.